Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CUV1647 for erythropoietic protoporphyria
ACTRN12607000261415Phase 3Active, not recruiting
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Jun 2007
- Modality
- Small Molecules, Peptides
- Countries
- 5
01
Overview
Phase 3 trial of Afamelanotide in erythropoietic protoporphyria (EPP) (2 arms), sponsored by Clinuvel Pharmaceuticals. Primary endpoints: Number of phototoxic reactions and Severity of phototoxic reactions. Started Jun 2007; status: active, not recruiting.
02
Drugs
Afamelanotide
03
Conditions
erythropoietic protoporphyria (EPP)
Beyond the preview
Go deeper on ACTRN12607000261415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000261415.